Frequently Asked Questions:
The COVID-19 outbreak negatively impacted the market due to the transformation of the healthcare system to manage COVID-19 has resulted in medication launch cancellations and clinical trial delays.
North America accounted for the major revenue share in the bacterial vaginosis drug market.
The major drivers responsible for the market’s growth include the rising frequency of bacterial infections and vaginosis, increased research and development efforts, and awareness about women’s health.
The Rx segment had a major share in the global market in 2021.
The hospital segment had a major share in the global market.